Yan-Ping Ren
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yan-Ping Ren has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Chao Kang
College of Life Science and Technology, Guangxi University, Nanning, Guangxi, China
1 shared publication Chao-Ying Zhao
College of Basic Medical Sciences, Zunyi Medical University, Zunyi, China
1 shared publicationChun-Hua Xing
College of Basic Medical Sciences, Zunyi Medical University, Zunyi, China
1 shared publicationDeng-Wang Chen
Department of Histology and Embryology, Zunyi Medical University
1 shared publication- Deshun Shi
Guangxi Key Laboratory of Animal Breeding, Disease Control and Prevention, College of Animal Science and Technology, Guangxi University, Nanning 530004, China
1 shared publication Ji-Dong Zhang
Department of Immunology, Zunyi Medical University
1 shared publication
Latest Publications
- Open Access
- 3 February 2026
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 14, 1744305
Unraveling the complex web: pathogenesis and prevention of gestational diabetes mellitus-related fetal overgrowth
Fetal overgrowth, manifesting as large for gestational age or macrosomia, remains a common complication of gestational diabetes mellitus (GDM) with neonatal and long-term metabolic implications. While maternal hyperglycemia is a key driver, evidence describes the role of dysregulated placental nutrient transport involving glucose, amino acids, and lipids mediated by signaling hubs like mTOR, IGF, and AMPK. Beyond traditional metabolic axes, this review explores emerging contributors, including gut microbiota dysbiosis and extracellular vesicle mediated communication, which modulate the environment. We synthesize evidence on fetal vascular adaptations and epigenetic programming underpinning accelerated growth. Clinically, achieving euglycemia often fails to eliminate residual overgrowth risks completely. Management is evolving to integrate advanced ultrasonic markers, such as fetal abdominal fat layer thickness, and pharmacotherapeutic candidates like metformin or pravastatin. However, addressing critical knowledge gaps requires robust longitudinal cohorts and rigorous causal inference to validate complex mechanisms. Furthermore, implementing standardized biomarker protocols remains essential for clinical translation. This review provides a comprehensive framework for precision-based strategies to manage GDM-related fetal overgrowth effectively. Search Strategy. A systematic search of PubMed, Web of Science, and Google Scholar was conducted for literature published up to 2025. The search utilized a combination of the following keywords and their variants: “gestational diabetes mellitus,” “fetal overgrowth,” “macrosomia,” “placental transport,” “insulin resistance,” “mTOR,” “extracellular vesicles,” “microbiome,” and “epigenetics.” Boolean operators (AND, OR) were applied. Priority was given to human clinical studies, meta-analyses, and large cohort studies, with animal and in vitro experiments included as mechanistic supplements.
- 3 February 2026
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 14, 1744305
Open AccessUnraveling the complex web: pathogenesis and prevention of gestational diabetes mellitus-related fetal overgrowth
Fetal overgrowth, manifesting as large for gestational age or macrosomia, remains a common complication of gestational diabetes mellitus (GDM) with neonatal and long-term metabolic implications. While maternal hyperglycemia is a key driver, evidence describes the role of dysregulated placental nutrient transport involving glucose, amino acids, and lipids mediated by signaling hubs like mTOR, IGF, and AMPK. Beyond traditional metabolic axes, this review explores emerging contributors, including gut microbiota dysbiosis and extracellular vesicle mediated communication, which modulate the environment. We synthesize evidence on fetal vascular adaptations and epigenetic programming underpinning accelerated growth. Clinically, achieving euglycemia often fails to eliminate residual overgrowth risks completely. Management is evolving to integrate advanced ultrasonic markers, such as fetal abdominal fat layer thickness, and pharmacotherapeutic candidates like metformin or pravastatin. However, addressing critical knowledge gaps requires robust longitudinal cohorts and rigorous causal inference to validate complex mechanisms. Furthermore, implementing standardized biomarker protocols remains essential for clinical translation. This review provides a comprehensive framework for precision-based strategies to manage GDM-related fetal overgrowth effectively. Search Strategy. A systematic search of PubMed, Web of Science, and Google Scholar was conducted for literature published up to 2025. The search utilized a combination of the following keywords and their variants: “gestational diabetes mellitus,” “fetal overgrowth,” “macrosomia,” “placental transport,” “insulin resistance,” “mTOR,” “extracellular vesicles,” “microbiome,” and “epigenetics.” Boolean operators (AND, OR) were applied. Priority was given to human clinical studies, meta-analyses, and large cohort studies, with animal and in vitro experiments included as mechanistic supplements.
- Open Access
- 28 February 2022
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 10, 834964
Acrylamide Exposure Destroys the Distribution and Functions of Organelles in Mouse Oocytes
Acrylamide (ACR) is a common industrial ingredient which is also found in foods that are cooked at high temperatures. ACR has been shown to have multiple toxicities including reproductive toxicity. Previous studies reported that ACR caused oocyte maturation defects through the induction of apoptosis and oxidative stress. In the present study, we showed that ACR exposure affected oocyte organelle functions, which might be the reason for oocyte toxicity. We found that exposure to 5 mM ACR reduced oocyte maturation. ACR caused abnormal mitochondrial distribution away from spindle periphery and reduced mitochondrial membrane potential. Further analysis showed that ACR exposure reduced the fluorescence intensity of Rps3 and abnormal distribution of the endoplasmic reticulum, indicating that ACR affected protein synthesis and modification in mouse oocytes. We found the negative effects of ACR on the distribution of the Golgi apparatus; in addition, fluorescence intensity of vesicle transporter Rab8A decreased, suggesting the decrease in protein transport capacity of oocytes. Furthermore, the simultaneous increase in lysosomes and LAMP2 fluorescence intensity was also observed, suggesting that ACR affected protein degradation in oocytes. In conclusion, our results indicated that ACR exposure disrupted the distribution and functions of organelles, which further affected oocyte developmental competence in mice.
- 28 February 2022
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 10, 834964
Open AccessAcrylamide Exposure Destroys the Distribution and Functions of Organelles in Mouse Oocytes
Acrylamide (ACR) is a common industrial ingredient which is also found in foods that are cooked at high temperatures. ACR has been shown to have multiple toxicities including reproductive toxicity. Previous studies reported that ACR caused oocyte maturation defects through the induction of apoptosis and oxidative stress. In the present study, we showed that ACR exposure affected oocyte organelle functions, which might be the reason for oocyte toxicity. We found that exposure to 5 mM ACR reduced oocyte maturation. ACR caused abnormal mitochondrial distribution away from spindle periphery and reduced mitochondrial membrane potential. Further analysis showed that ACR exposure reduced the fluorescence intensity of Rps3 and abnormal distribution of the endoplasmic reticulum, indicating that ACR affected protein synthesis and modification in mouse oocytes. We found the negative effects of ACR on the distribution of the Golgi apparatus; in addition, fluorescence intensity of vesicle transporter Rab8A decreased, suggesting the decrease in protein transport capacity of oocytes. Furthermore, the simultaneous increase in lysosomes and LAMP2 fluorescence intensity was also observed, suggesting that ACR affected protein degradation in oocytes. In conclusion, our results indicated that ACR exposure disrupted the distribution and functions of organelles, which further affected oocyte developmental competence in mice.
- Open Access
- 1 January 2015
- Published by Springer Nature in BMC Veterinary Research
- Vol. 11 (1) , 36
Establishment of a mouse model to express bovine CD14 short hairpin RNA
Cluster of differentiation 14 (CD14) functions as a co-receptor for Toll-like receptor (TLR)-4 and myeloid differentiation factor (MD)-2 in detecting bacterial lipopolysaccharide. Together, these complexes promote the phagocytosis and digestion of Gram-negative bacteria, and initiate immune responses. To date, much of our understanding of CD14 function during Gram-negative bacterial inflammation comes from studies on mouse knockout models and cell transfection. To identify the effect of CD14 knockdown in this process in large livestock animals, we established a mouse model expressing bovine CD14 short hairpin (sh) RNA. shRNA fragments targeting bovine CD14 were screened by co-transfection in HEK 293 cells, and the most effective CD14 shRNA fragment was cloned into the eukaryotic expression vector pSilencer4.1-CD14 shRNA-IRES (internal ribosome entry site) and transferred into mouse zygotes by pronuclear microinjection to obtain transgenic mice. Expression of the enhanced green fluorescent protein (EGFP) reporter and genes related to the TLR4 signaling pathway was detected by immunohistochemistry (IHC) and quantitative polymerase chain reaction (PCR), respectively. One effective shRNA fragment (shRNA-674) targeting bovine CD14 was obtained, the sequence of which was shown to be conserved between cows, buffalos, sheep, and humans. Thirty-seven founder pups were obtained by pronuclear microinjection, of which three were positive for the transgene. In the F1 generation, 11 of 33 mice (33%) were positive for the transgene as detected by PCR. IHC analysis detected exogenous EGFP expression in the liver, kidney, and spleen of transgenic F1 mice, indicating that they were chimeric. The expression of endogenous CD14 mRNA in the heart, liver, spleen, lung, and kidney of transgenic F1 mice was decreased 8-, 3-, 19.5-, 6-, and 11-fold, respectively. The expression patterns of endogenous MD-2, TLR4, interleukin-6 and tumor necrosis factor-α genes in transgenic mice also varied. This study confirms that transgenic mice expressing bovine CD14 shRNA can be generated by pronuclear microinjection, and demonstrates inhibited endogenous mouse CD14 expression that alters gene expression related to the TLR4 signaling pathway.
- 1 January 2015
- Published by Springer Nature in BMC Veterinary Research
- Vol. 11 (1) , 36
Open AccessEstablishment of a mouse model to express bovine CD14 short hairpin RNA
Cluster of differentiation 14 (CD14) functions as a co-receptor for Toll-like receptor (TLR)-4 and myeloid differentiation factor (MD)-2 in detecting bacterial lipopolysaccharide. Together, these complexes promote the phagocytosis and digestion of Gram-negative bacteria, and initiate immune responses. To date, much of our understanding of CD14 function during Gram-negative bacterial inflammation comes from studies on mouse knockout models and cell transfection. To identify the effect of CD14 knockdown in this process in large livestock animals, we established a mouse model expressing bovine CD14 short hairpin (sh) RNA. shRNA fragments targeting bovine CD14 were screened by co-transfection in HEK 293 cells, and the most effective CD14 shRNA fragment was cloned into the eukaryotic expression vector pSilencer4.1-CD14 shRNA-IRES (internal ribosome entry site) and transferred into mouse zygotes by pronuclear microinjection to obtain transgenic mice. Expression of the enhanced green fluorescent protein (EGFP) reporter and genes related to the TLR4 signaling pathway was detected by immunohistochemistry (IHC) and quantitative polymerase chain reaction (PCR), respectively. One effective shRNA fragment (shRNA-674) targeting bovine CD14 was obtained, the sequence of which was shown to be conserved between cows, buffalos, sheep, and humans. Thirty-seven founder pups were obtained by pronuclear microinjection, of which three were positive for the transgene. In the F1 generation, 11 of 33 mice (33%) were positive for the transgene as detected by PCR. IHC analysis detected exogenous EGFP expression in the liver, kidney, and spleen of transgenic F1 mice, indicating that they were chimeric. The expression of endogenous CD14 mRNA in the heart, liver, spleen, lung, and kidney of transgenic F1 mice was decreased 8-, 3-, 19.5-, 6-, and 11-fold, respectively. The expression patterns of endogenous MD-2, TLR4, interleukin-6 and tumor necrosis factor-α genes in transgenic mice also varied. This study confirms that transgenic mice expressing bovine CD14 shRNA can be generated by pronuclear microinjection, and demonstrates inhibited endogenous mouse CD14 expression that alters gene expression related to the TLR4 signaling pathway.